FDA Orders Withdrawal of Andexxa: Doubled Risk of Fatal Blood Clots Leads to Market Removal
“The FDA’s decision to withdraw Andexxa from the market underscores a critical failure in post-market surveillance and patient safety,” states Greg Vigna, MD, JD, national medical malpractice attorney. The U.S.…